Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Marie Skłodowska-Curie Action · Running

THERABOT Therapeutic Bacteria Biohybrids For Oncology Treatment

Coordinator
Institut National De La Sante Et De La Recherche Medicale, France
Runs
1 January 2025 to 31 December 2028
Status
Running
EU funding
€1.5m
Total cost
—
Partners
14 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101182953

What the project is doing

In the project's own words, from its summary on CORDIS.

THERABOT pioneers a groundbreaking approach in the fight against cancer through the development of engineered biohybrid agents, iBots. These iBots represent a significant leap in bacterial cancer therapy (BCT), combining synthetic biology and nanotechnology to encapsulate therapeutic bacteria with protective polymeric coatings. This encapsulation aims to enhance the delivery and efficacy of bacteria to colonize tumor tissue, drastically reducing the adverse immune responses and systemic toxicity associated with traditional BCT.

THERABOT's innovative strategy focuses on colorectal cancer, employing a multifaceted approach that includes the design of advanced intelligent biohybrids by programming iBots for targeted therapeutic action, and validating their effectiveness in vivo. Central to THERABOT's mission is its interdisciplinary and international consortium, comprising 12 members from 10 leading academic institutions and 2 SMEs across Europe (France, Spain and Sweden) and from non-EU countries (Japan, Argentina, Chile, Brazil and Thailand).

This collaboration fosters a unique integration of diverse scientific disciplines, including bioengineering, immunology, material science and oncology, promoting the exchange of knowledge, techniques, and cultural perspectives, which is pivotal for addressing the complex challenges of developing a new cancer therapy. THERABOT not only emphasizes the scientific innovation but also prioritizes the training and career development of seconded staff, enhancing their research competencies and preparing them for future challenges in diverse fields.

THERABOT's focus on developing accessible and patient-friendly cancer treatments, underscores its alignment with EU priorities in health and innovation. By redefining cancer treatment paradigms towards more precise, effective, and personalized approaches, our project aspires to have a lasting impact on society, improving patient outcomes, and contributing to the global fight against cancer.

Topics

Who is involved

OrganisationCityCountryRole
Institut National De La Sante Et De La Recherche MedicaleParisFranceCoordinator
Consejo Nacional De Investigaciones Cientificas Y Tecnicas (conicet)Buenos AiresARAssociatedpartner
Universidad Nacional Del LitoralSanta FeARAssociatedpartner
Universidad Nacional Del SurBahia BlancaARAssociatedpartner
Universidade Federal de Juiz de ForaJuiz De ForaBrazilAssociatedpartner
Pontificia Universidad Catolica De ChileSantiagoCLAssociatedpartner
Universidad Tecnologica MetropolitanaSantiagoCLAssociatedpartner
Asociacion Centro De Investigacion Cooperativa En Biomateriales- Cic BiomaguneSan SebastianSpainParticipant
Indicate Solutions, SLDonostia/San SebastianSpainParticipant
A5 ScienceAix En ProvenceFranceParticipant
National Institute of Advanced Industrial Science and TechnologyTokyoJapanAssociatedpartner
National University Corporation the University of TokyoTokyoJapanAssociatedpartner
Uppsala UniversitetUppsalaSwedenParticipant
Chulalongkorn UniversityBangkokTHAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI